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Introduction
BRAF is the most frequently mutated protein kinase in human cancer (1) Melanoma with V600E BRAF mutation is a case in point (2) . Sorafenib activity is not linked to the presence of a BRAF mutation in the tumor and is more likely due to its antiangiogenic effect. Sorafenib is efficient and has been approved for the treatment of metastatic renal carcinoma (3)(4) and advanced hepatocellular carcinoma (4) independently of the mutational status of BRAF.
In spite of their variability in terms of BRAF selectivity and clinical activity, all three RAF inhibitors are associated with one and the same intriguing cutaneous side effect which is the emergence of borderline squamous cell neoplasms. Indeed, we and others have reported single or multiple cutaneous keratoacanthomas (KA) and squamous cell carcinomas (SCC) during treatment with sorafenib(5-9). These paradoxical keratinocyte proliferations arise in 6-7% of patients (5; 10). The induction of KA and SCC is even more frequent with vemurafenib and GSK2118436, and has been described in 15 to 25% of the patients(2; 10) .
We undertook a translational research in the aim of understanding the mechanisms of these skin cancer inductions. We first performed a detailed clinical, pathological and molecular study of the skin neoplasms arising in patients treated with sorafenib. We then looked at the biological effects of sorafenib in vivo on normal skin samples from patients treated with sorafenib or a placebo. In parallel, we analyzed the effect of sorafenib in vitro on cultured keratinocytes. We found that sorafenib exposure was associated with increased MAPK pathway activation and keratinocyte proliferation ex vivo and in vivo. Sorafenib induced dosedependent BRAF/CRAF dimerization associated with strong activation of CRAF in cultured keratinocytes. Finally, oncogenic mutations in HRAS TGFBR1 and TP53 were detected in several benign or malignant skin tumors. Altogether, our results suggest that sorafenib induces a continuous spectrum of keratinocyte changes and proliferation via the paradoxical activation of the MAPK pathway in keratinocytes associated with BRAF/CRAF heterodimerization and subsequent CRAF activation. Additional events such as a HRAS mutation or EGFR activation giving rise to MAPK pathway co-activation might be required for full transformation of keratinocytes.
Material and methods

Patients and skin samples:
Thirty-one skin lesions diagnosed as follicular cystic skin lesions, perforating folliculitis, KA or SCC originating from 17 patients treated with sorafenib from 2005 to 2010 were studied.
For each patient, the tumor type, duration of sorafenib therapy before the emergence of the skin tumor and the clinical description of the skin lesions are reported. Four μm sections from formalin-fixed, paraffin-embedded biopsy samples of skin lesions were stained with hematoxylin and eosin and independently read by two pathologists.
Research. Normal skin samples from patients included in the TARGET study, evaluating sorafenib versus a placebo in patients with renal cell cancer were also studied (3). Normal skin biopsy samples were collected from the forearms of patients who received sorafenib or a placebo for 6 weeks.
Each skin sample was cut into 4-μm sections, formalin-fixed, paraffin-embedded and stained with hematoxylin and eosin. A section from each case was analyzed immunochemically for Ki67 (monoclonal MIB-1, DAKO, Carpintera, CA) and phospho-ERK protein (monoclonal 20G11, Cell signaling technology, Boston, MA). Slides were deparaffinized and treated with an alcohol gradient to absolute ethanol. Endogenous peroxidase activity was blocked with the Peroxydase blocking solution (DAKO, S2001, Carpintera, CA). Antigen retrieval was achieved with Target Retrieval Solution (DAKO). Primary antibody was applied at 1:100 dilution and incubated at 4°C for 1 hour. Anti-mouse IgG with the DAKO Envision system (horseradish peroxidase) was employed according to the manufacturer's instructions.
Research. Sequences were analyzed by Sanger direct sequencing performed after Polymerase Chain Reaction (PCR) amplification of target exons. Sequencing reactions were carried out using the BigDye® Terminator Cycle Sequencing Kit software according to the manufacturer's recommendations (Applied Biosystems, Forster City, CA). The primer sequences are available upon request. Sequencing reactions were analyzed on a 48-capillary 3730 DNA Analyzer®. Sequence reading and alignment were performed with SeqScape® software (Applied Biosystems). All detected mutations were confirmed following at least one independent PCR reaction.
In vitro experiment using HaCat keratinocytes
Cell culture: HaCat keratinocytes were cultured in DMEM (Invitrogen) containing 10% fetal calf serum (FCS; Perbio) and antibiotics (penicillin/streptomycin; Invitrogen). Cellular proliferation was evaluated using the CellTiter assay (Promega). Sorafenib and PD153035 used for cell treatment was purchased from Alexis Biochemicals and dissolved in DMSO.
Protein expression: Cells were lysed in 50 mM Tris (pH 7,5), 150 mM NaCl, 0,5% NP40, 5 mM NaF, 2 mM Na 3 VO 4 , 10 μg/ml leupeptin, and 10 μg/ml aprotinin. 
RNA interference:
HaCat cells were transfected with a siRNA control (SCR) or targeting BRAF or CRAF as previously described (11).
Statistics :
Simple univariate descriptive statistics were used to compare the population, using the t-test with a 5% significance level.
Research. 
Results
Clinical and pathological characterization of skin lesions:
The gender, age, cancer type, daily dose of sorafenib, time interval between the start of sorafenib therapy and the first skin symptom, the number and types of lesions as well as the skin sites involved are detailed in table 1.
Various clinical aspects were observed but all patients developed small cystic follicular lesions that most frequently affected the face and also sometimes other parts of the skin such as the buttocks, axilla or inguinal areas (table 1). They occurred 3 to 5 months after the initiation of sorafenib. Cysts on the face were dominantly non inflammatory millimetric small and white lesions. Inflammatory cystic lesions exhibited erythematous hyperkeratotic papules, with a central, cone-shaped plug.
Lesions clinically suggestive of perforating folliculitis, meaning a more inflammatory infiltrate with a keratotic appearance occurred mostly on the buttocks and the upper part of the limbs (patients # 7, 11, 12, 13 and 14) .
Patients 1 to 11 developed at least one lesion characteristic of KA or of KA-like SCC.
Clinically, they were fast-growing firm round nodules with a central crateriform keratotic zone. Three of these patients had multiple skin lesions (patients # 4, 6, 7) occurring 1 to 9 months after the initiation of sorafenib.
A total of 22 lesions were excised and the pathological examination using H&E staining revealed a spectrum of lesions ( Figure. beaks with no cytological atypia nor invasion, iiii) crateriform KA-like SCC defined as crateriform epidermal neoplasms with irregular budding borders, cytological atypia and invasive nests (figure 1). Lymphatic metastatic embols were seen in one SCC (patient #8).
Patient #7 developed the entire spectrum of the skin lesions that were observed: non inflammatory facial cysts, cystic folliculitis, perforating folliculitis, multiple KA and SCC that emerged respectively 3 to 5 months after the initiation of sorafenib. Sorafenib was stopped due to cutaneous intolerance at the request of the patient after 24 months even though it was still effective against the progression of the renal cell carcinoma. All of her skin lesions, including skin tumors disappeared over a 4-month period following sorafenib interruption.
Oncogenic mutations
Eight oncogenic mutations were found in benign and malignant tumors. Three HRAS mutations on codons 12 or 13 were found in three lesions: one KA, one KA-like SCC and one case of benign perforating folliculitis (table 1) Six of these mutations are known to be typically UV-induced (Table 1) . (13, 14) Normal skin biopsy specimens :
The results of the immunostaining of normal skin samples with Ki67 and pERK for patients treated with sorafenib or a placebo are shown in figure 2.
Ki67 staining was found in the nucleus of a few scattered basal cells in non treated patients while it was found in the nucleus of 1 to 2 whole layers or multiple heaps of basal cells in We also found a tendency for increased phosphorylation of ERK in normal skin of sorafenibtreated patients compared to normal skin of placebo-treated patients. A strong positive p-ERK staining was found in 7 out of 11 normal skin samples from sorafenib-treated patients (64%) whereas only 2 out of 8 samples from placebo-treated patients (25%) showed positive, albeit weak and focal p-ERK staining (figure 2 C & D) (p= 0.1 Fisher exact test). The lack of statistical significance might be due here to the small number of specimen.
In vitro results on HaCat keratinocytes
We first used sequencing to verify that HaCat cells did not harbor an oncogenic mutation in any of the RAS genes (HRAS, KRAS and NRAS) (data not shown).
HaCat cells were treated with increasing amounts of sorafenib and BRAF-CRAF heterodimerization was evaluated using co-immunoprecipitation experiments. We did not detect any heterodimers in DMSO-treated cells whereas sorafenib induced BRAF-CRAF heterodimers in a dose-dependent manner in keratinocytes (Figure 3 A) . As BRAF-CRAF heterodimerization was previously shown to activate CRAF, we measured CRAF kinase activity in keratinocytes treated with increasing doses of sorafenib. Of note, sorafenib is a reversible inhibitor and therefore was no longer present during the in vitro kinase assay. To determine whether this dual effect on cell proliferation could be explained by the action of sorafenib on the anti-apoptotic molecule MCL1, MCL1 expression was studied as a function of sorafenib concentration. We found that MCL1 expression decreased with higher sorafenib concentrations, (3 and 10 μM), whereas 1 μM of sorafenib did not influence MCL1 expression (figure 4 C). To test whether sorafenib-induced heterodimerization could be detected in situ, we used a Proximity Ligation Assay (PLA). In this assay, a pair of oligonucleotide-labeled secondary antibodies (PLA probes) generates a signal only when they have bound in close proximity, thus allowing the detection of protein-protein interaction in situ. HaCat cells were treated or not with sorafenib and fixed. BRAF-CRAF heterodimerization was visualized by PLA using a combination of a CRAF and a BRAF antibody. Figure 5 shows that sorafenib-induced BRAF-CRAF heterodimerization can be directly detected in keratinocytes.
RNA interference confirmed the specificity of the PLA signal as inhibition of BRAF or CRAF expression with siRNA strongly diminished the PLA signal induced by sorafenib (Supplementary Figure 1) .
DISCUSSION
Targeted anticancer agents are associated with frequent and diverse cutaneous side effects.
The description and study of these skin manifestations is of critical importance. Indeed, they frequently have an adverse impact on the patient's quality of life and understanding their underlying mechanisms is certainly the best way to treat these skin manifestations in addition to offering new perspectives on skin biology (5; 6; 12-14)
Our earlier observations of skin manifestations induced by targeted agents had lead us to formulate the hypothesis that sorafenib-induced KA and skin SCC were due to its effect on RAF kinases. Indeed, these side effects were not seen after blockade of VEGFR, KIT, FLT3 or PDGFR, the other sorafenib targets (5; 12) . Our hypothesis was further corroborated by the description of KA and SCC occurring with more specific BRAF inhibitors: vemurafenib and GSK2118436 (2; 15) In the present work, we present a series of 31 skin lesions occurring in 17 patients treated with sorafenib 1 to 9 months after the beginning of the therapy. The lesions were benign and borderline or malignant skin tumors which might seem paradoxical since they occurred while under therapy with an anti-proliferative agent.
The entity KA as a distinct tumor at the crossroad between benign and malignant tumors has been debated for decades. KA is a rapidly growing keratotic and crateriform tumor, very similar clinically and pathologically to well differentiated SCC (16) 
squamous epithelioma (MSSE) also called Ferguson Smith disease (19) . Our pathological classification between KA and SCC depended on the existence of cytological atypia, invasive nests or lymphatic metastatic embols. When any of these sign were seen, we classified the crateriform epidermal neoplasms limited by sharp beaks as KA-like SCCs. When neither atypia, nor invasion was associated with the crateriform lesion, they were considered as KAs.
The first hypothesis that we put forward following our clinical and pathological studies of these tumors was that they seemed to belong to a common spectrum of lesions with the possibility of transition from benign lesions, i.e. from a cystic more or less inflammatory lesion to KA and SCC. This "continuity" hypothesis is based on several observations. First, several of our patients had associated benign and malignant tumors. All of them had several benign cystic lesions, in addition to the lesions that were biopsied and studied (table 1) Second, all of these lesions seemed to have developed at the expense of or around hair follicles. Follicular dystrophic lesions and perforating folliculitis are obviously follicular lesions and relics of hair follicles were indeed observed in every biopsy sample. Follicular ontogeny for KA is also well documented (20) . The microscopically lamellar structure as well as the type of cytokeratins found in KA suggest that they are hair follicle-derived tumors (21) . Thus, our first hypothesis is that all these proliferative epidermal lesions could represent various steps of a same generic process initiated by RAF inhibition in the skin and particularly targeting follicular keratinocytes. To explore the biological effect of sorafenib on normal skin in vivo, we studied normal skin samples of patients treated with sorafenib or a placebo. Our results showed a significant increase in keratinocyte proliferation, and no decrease of ERK phosphorylation, but, on the contrary, a clear tendancy to an increase of ERK phosphorylation levels in the skin after treatment with sorafenib. We now have preliminary data on normal skin samples from (22) . In both models, this activation requires wt BRAF together with an additional activation signal of the pathway, as is the case with RAS or EGFR activation. To understand whether this effect could explain keratinocyte proliferation in response to sorafenib, we used HaCat keratinocytes to see if we could reproduce these results in an in vitro system. We showed that sorafenib indeed regulates the activation of the MAPK pathway and cellular proliferation in keratinocytes in a dose-and time-dependent manner with an increase of both parameters when the dose of sorafenib was low (1 μM). For higher sorafenib concentrations (3 and 10 μM) the effect on ERK phosphorylation was transient and disappeared after one hour, and the effect on proliferation was rather inhibitory. This is in line with the transactivation model (22) where RAF inhibitors activate ERK signaling at low concentrations but inhibit it at higher concentrations in wt BRAF cells. The decreased effect of higher concentrations of sorafenib on ERK phosphorylation could be explained by the direct binding and inhibiting activity of the drug on CRAF. As sorafenib has been previously shown to regulate the expression of the anti-apoptotic MCL1 molecule (25; 26) , we explored the effect of various doses of sorafenib on MCL1 expression. We found that the regulation of MCL1 expression was dependent on sorafenib concentration with inhibited MCL1 expression at higher drug doses. This effect of high doses (3 and 10 ȝM) of sorafenib on MCL1 expression could explain that, although sorafenib activated ERK at all doses tested, it inhibits cell proliferation at higher doses. Thus, the complex action of sorafenib on the activation of the MAPK kinase pathway and on cell proliferation is dose-dependent and results from the combined effects of the drug on RAF kinase inhibition on the one hand and on the control of apoptosis via MCL1 regulation on the other hand. We were able to detect the
formation of BRAF-CRAF dimers in vitro by co-immunoprecipitation and directly in cells by
PLA for all sorafenib concentrations tested. This dimerization-induced CRAF activation in keratinocytes can explain MAPK activation at least at a low sorafenib concentration which might be the case in the skin. Indeed, the plasma sorafenib concentration in clinical therapeutic use ranges from 3 to 6 mg/l (6.5 to 13 μM) but the drug concentration in the skin is probably much lower than in plasma due to high protein binding (27) . In most experimental cell lines models used, RAS activation seems required for RAF dimerization. We show here that RAS is not mutated in the HaCat keratinocytes and is rarely mutated in our biopsy specimen, however, it is possible that RAS is activated by upstream signaling like EGFR activation, which is very frequently observed in the skin. . Indeed we showed that when EGFR activity was inhibited with PD153035 in HaCat cells, sorafenib could not induce RAF heterodimerization anymore (Supplementary Figure 2) . This result shows that activation of the pathway upstream of RAF, presumably including RAS activation, is necessary for sorafenib-induced RAF dimerization in keratinocytes. Our data are therefore consistent with and benign cystic folliculitis that did not harbor any mutation, meaning that the TGFBR1 mutation was somatic and not germinal ( Table 1 ).
The lesions presented by patients with MSSE are clinically and pathologically very similar to lesions presented in the context of RAF inhibitor treatment suggesting an effect of these drugs on the TGFB/TGFBR signaling pathway that warrants further exploration.
Six of the mutations found in our samples are known to be potentially UV-induced (patients # 1, 3, 4, 6, 10and 14), either located on typical UV sensitive dipyrimidine sites (patients #1, 3, 6, 10, 14) or on an ACA sequence known to give rise to a mutagenic photoproduct (patient #4) (35; 36) . Oncogenic events such as TP53 mutations are found in normal skin keratinocytes on sun-exposed areas (37). Indeed, a recent paper demonstrated that intermittently sun-exposed skin contained an extensive number of intact cells with TP53 
mutations, with an estimated annual rate of 35.000 new persistent TP53 mutations per individual(38) . In accordance with this hypothesis, the six lesions that were harboring mutations with UV-signature were located on sun-exposed areas, whereas, the two remaining mutations (patients #7 and 12) were found on non-exposed skin areas (palm and buttocks), (Table 1) . Thus, sorafenib-induced skin tumor might result from the combined effect of paradoxical MAPkinase pathway activation and co-existing or even pre-existing oncogenic mutations that could have been generated by UV rays action on normal skin.
Altogether, the fact that we found oncogenic TP53, TGFBR1 and RAS mutations with an UV signature suggests that it is a probably wise move to advise patients receiving sorafenib or other RAF inhibitors to use efficient photoprotective measures.
The fact that we did not find oncogenic mutations in the other malignant lesions could be due to the existence of other mutations that we did not look for or by alternate ways of activating the MAPKinase pathway such as EGFR activation. Indeed, EGFR can also be activated in the skin by various stimuli such as physiologic sun exposure or wound healing.(28; 29)and its activation is sufficient to promote RAF dimerization in keratinocytes treated with sorafenib (Supplementary Figure 2) .
It is possible that sun-induced RAF or TP53 mutation or EGFR activation were present in the keratinocyte prior to BRAF inhibition, and could have led to keratinocyte transformation in the presence of sorafenib. In some of our samples, a mutational event existing prior to malignant transformation is supported by the fact that we found oncogenic mutations of HRAS and TP53 in two benign cystic lesions.
Recently, oncogenic RAS mutations, (mostly HRAS) were found at a higher frequency in 71% 
